Stefan Hansson

Professor, consultant, PI

Personal profile

Research

My research focus is on preeclampsia. Based on findings from protein- and gene array studies, free fetal hemoglobin has been shown to be a potential new predictive- and diagnostic marker for preeclampsia. We are now focusing on a new potential treatment for preeclampsia based on a free hemoglobin scavenger, alpha-1-microglobulin (A1M).

Societal impact

Free fetal hemoglobin as a potential new predictive- and diagnostic marker for preeclampsia is further developed in a biotech company, Preelumina Diagnostics, that I am cofounder of. I am also cofunder of A1M Pharma, a company that is developing a new potential therapeutic drug for preeclampsia.

Expertise related to UN Sustainable Development Goals

In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):

  • SDG 3 - Good Health and Well-being
  • SDG 11 - Sustainable Cities and Communities

UKÄ subject classification

  • Obstetrics, Gynecology and Reproductive Medicine

Free keywords

  • Preeclampsia
  • free fetal hemoglobin
  • alpha-1-microglubin

Fingerprint

Dive into the research topics where Stefan Hansson is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
  • 1 Similar Profiles

Collaborations the last five years

Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
  • SAFT "Obstetrik och anestesi"

    Thomas, O. (Organiser), Persson, K. (Chair), Tranberg Lindqvist, A. (Chair), Levin, K. (Session chair), Karlsson, O. (Invited speaker), Lykke, J. (Invited speaker), Hansson, S. (Invited speaker), Hörsel, E. (Invited speaker), Thorlacius, K. (Invited speaker) & Strevens, H. (Invited speaker)

    2019 Sept 8

    Activity: Participating in or organising an eventOrganisation of workshop/ seminar/ course